Page 2 - Menarini Stemline News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Menarini Group: Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

The Menarini Group: Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesMenarini stemlineElcin barker ergunAlex zhavoronkovCheya popeMenarini groupStemline therapeutics incSan antonio breast cancer symposiumStemline therapeuticsInsilico medicinePharma generative

Insilico nabs $500M+ biobucks deal for preclinical cancer asset

Insilico nabs $500M+ biobucks deal for preclinical cancer asset
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Menarini stemlineElcin barker ergunMenarini group stemline therapeuticsMenarini groupStemline therapeuticsInsilico medicineBarker ergun

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients.

San antonioUnited statesMenarini stemlineElcin barker ergunCheya popeMenarini industrie farmaceutiche riuniteAlex zhavoronkovValeria speroni cardiMenarini groupStemline therapeutics incSan antonio breast cancer symposiumStemline therapeuticsInsilico medicinePharma generativeIndustrie farmaceuticheBrita belli

MHRA grants regulatory-first for endocrine therapy in decades

MHRA grants regulatory-first for endocrine therapy in decades
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

United kingdomMount vernonGlasgow cityRick coopeMenarini stemlineEuropean medicines agencyRegulatory agencyUnited kingdom medicinesStemline united kingdomProfessor david milesMedical oncologyMount vernon cancerGeneral manager

Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU(R) (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023

This new post hoc analysis of the Phase 3 EMERALD trial evaluatedelacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of at least 12 months) with tumors harboring ESR1 mutations.This analysisshows a clinically meaningful

United statesElcin barker ergunMenarini stemlineMenarini groupElacestrant clinical development programUt health san antonioMenarini group stemline therapeuticMd anderson cancer centerStemline therapeutics incStemline therapeuticsAntonio breast cancer symposiumVirginia kaklamaniSan antonioSafety informationStemline therapeuticFetal toxicity